Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial - Maher, TM; Tudor, VA; Saunders, P (The Lancet Respiratory Medicine, 2023)
et al.